Clinical Trial

Effect of Dapagliflozin on Right Ventricular-Pulmonary Artery Coupling After Off-Pump Coronary Atery Bypass Grafting

Study acronym: DAPA-RV-CABG
Recruiting
View on ClinicalTrials.gov →
Summary
This prospective, single-center observational study evaluates the effect of dapagliflozin 10 mg/day on right ventricular-pulmonary artery coupling measured by the TAPSE/PASP ratio in 72 patients with left ventricular ejection fraction \<50% after off-pump coronary artery bypass grafting (OPCAB). The primary outcome is the change in TAPSE/PASP ratio from 1 month after surgery (before dapagliflozin) to 7 months after surgery (after 6 months of dapagliflozin therapy).
Protocol Amendment History 6 changes
critical Recruitment opened 2026-06-18
notable Primary completion pushed: 2027-11-01 -> 2028-05-01 2026-06-18
minor Completion pushed: 2028-01-01 -> 2028-07-01 2026-06-18
notable Sponsor changed: Samson Badalyan -> Pyatigorsk City Clinical Hospital Number 1 2026-06-05
notable Primary completion pushed: 2027-09-01 -> 2027-11-01 2026-06-05
minor Completion pushed: 2027-11-01 -> 2028-01-01 2026-06-05
Trial Details
NCT Number NCT07601867
Lead Sponsor Pyatigorsk City Clinical Hospital Number 1
Conditions Heart Failure, Coronary Arterial Disease
Enrollment 72 participants
Start Date 2026-07-01
Primary Completion 2028-05-01 (estimated)
Study Completion 2028-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-17